The Cambridge-based firm is set to directly list its ordinary shares on the New York Stock Exchange amid an increased focus on the US.
Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.
More from us
Did you know with a Plus subscription to Shropshire Star you get full access to our award winning journalism for the news that matters to you and more.
